Opebacan ophthalmic

Drug Profile

Opebacan ophthalmic

Alternative Names: BPI 21 ophthalmic; I-PREX; rBPI 21 ophthalmic; Recombinant bactericidal permeability increasing protein 21 ophthalmic

Latest Information Update: 03 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Class Antibacterials; Recombinant proteins
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Ocular inflammation; Ophthalmic infections

Most Recent Events

  • 15 Jul 2005 XOMA has terminated its license agreement with Zephyr Sciences for ophthalmic opebacan
  • 10 Nov 2004 Opebacan ophthalmic has been licensed to Zephyr Sciences worldwide
  • 24 Nov 2000 Allergan has returned all rights to I-PREX™ to XOMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top